ATE314863T1 - Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen - Google Patents

Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen

Info

Publication number: ATE314863T1
Authority: AT; Austria
Prior art keywords: heparin; binding affinity; growth factor; affinity growth; low
Prior art date: 1999-04-22

Application number

AT99915970T

Other languages

English (en)

Inventor

Shelly E Sakiyama-Elbert

Jeffrey A Hubbell

Original Assignee

Eidgenoess Tech Hochschule

Univ Zuerich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-22

Filing date

1999-04-22

Publication date

2006-02-15

1999-04-22 Application filed by Eidgenoess Tech Hochschule, Univ Zuerich filed Critical Eidgenoess Tech Hochschule

2006-02-15 Application granted granted Critical

2006-02-15 Publication of ATE314863T1 publication Critical patent/ATE314863T1/de

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 10
229960002897 heparin Drugs 0.000 title abstract 10
229920000669 heparin Polymers 0.000 title abstract 10
239000003102 growth factor Substances 0.000 title abstract 7
238000013270 controlled release Methods 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004169 proteins and genes Human genes 0.000 abstract 5
108090000623 proteins and genes Proteins 0.000 abstract 5
239000011159 matrix material Substances 0.000 abstract 4
230000015556 catabolic process Effects 0.000 abstract 2
238000006731 degradation reaction Methods 0.000 abstract 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 abstract 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 abstract 1
108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
102000015336 Nerve Growth Factor Human genes 0.000 abstract 1
230000021164 cell adhesion Effects 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
238000009792 diffusion process Methods 0.000 abstract 1
238000010494 dissociation reaction Methods 0.000 abstract 1
230000005593 dissociations Effects 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Zoology (AREA)
Transplantation (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT99915970T 1999-04-22 1999-04-22 Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen ATE314863T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/IB1999/000800 WO2000064481A1 (en)	1999-04-22	1999-04-22	Controlled release of growth factors from heparin containing matrices

Publications (1)

Publication Number	Publication Date
ATE314863T1 true ATE314863T1 (de)	2006-02-15

Family

ID=11004855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99915970T ATE314863T1 (de)	1999-04-22	1999-04-22	Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen

Country Status (9)

Country	Link
EP (1)	EP1178834B1 (de)
JP (1)	JP2002542301A (de)
AT (1)	ATE314863T1 (de)
AU (1)	AU3438199A (de)
CA (1)	CA2369579A1 (de)
DE (1)	DE69929323T2 (de)
ES (1)	ES2255257T3 (de)
MX (1)	MXPA01010567A (de)
WO (1)	WO2000064481A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8106001B2 (en) *	1996-08-27	2012-01-31	University Of South Florida	Diagnostic markers of human female infertility
US6894022B1 (en)	1998-08-27	2005-05-17	Eidgenossische Technische Hochschule Zurich	Growth factor modified protein matrices for tissue engineering
US7601685B2 (en)	1998-08-27	2009-10-13	Eidgenossische Technische Hochschule Zurich	Growth factor modified protein matrices for tissue engineering
JP4608173B2 (ja) *	2000-05-01	2011-01-05	イジュノシッヒテクニッヒホッフシューラチューリッヒ	組織を操作するための増殖因子改変タンパク質マトリクス
CA2445239C (en)	2001-04-25	2012-08-21	Eidgenossische Technische Hochschule Zurich	Drug delivery matrices to enhance wound healing
WO2003054146A2 (en)	2001-11-14	2003-07-03	Northwestern University	Self-assembly and mineralization of peptide-amphiphile nanofibers
US7247609B2 (en)	2001-12-18	2007-07-24	Universitat Zurich	Growth factor modified protein matrices for tissue engineering
AU2003215280A1 (en)	2002-02-15	2003-09-09	Northwestern University	Self-assembly of peptide-amphiphile nanofibers under physiological conditions
WO2004018628A2 (en)	2002-08-21	2004-03-04	Northwestern University	Charged peptide-amphiphile solutions & self-assembled peptide nanofiber networks formed therefrom
US7554021B2 (en)	2002-11-12	2009-06-30	Northwestern University	Composition and method for self-assembly and mineralization of peptide amphiphiles
US7683025B2 (en)	2002-11-14	2010-03-23	Northwestern University	Synthesis and self-assembly of ABC triblock bola peptide amphiphiles
WO2004072104A2 (en)	2003-02-11	2004-08-26	Northwestern University	Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
KR20070004560A (ko)	2003-12-05	2007-01-09	노오쓰웨스턴 유니버시티	성장 인자 전달을 위한 자가조립 펩티드 친양매성 화합물들및 관련 방법들
WO2005056576A2 (en)	2003-12-05	2005-06-23	Northwestern University	Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof
US7671012B2 (en)	2004-02-10	2010-03-02	Biosurface Engineering Technologies, Inc.	Formulations and methods for delivery of growth factor analogs
JP4895826B2 (ja)	2004-02-20	2012-03-14	バイオサーフェスエンジニアリングテクノロジーズ，インク．	骨形成蛋白−２の正のモジュレーター
WO2006073711A2 (en)	2005-01-06	2006-07-13	Kuros Biosurgery Ag	Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en)	2005-01-06	2013-11-05	Kuros Biosurgery Ag	Supplemented matrices for the repair of bone fractures
KR20070108555A (ko)	2005-03-04	2007-11-12	노오쓰웨스턴 유니버시티	혈관신생 헤파린 결합 펩티드 양친매성 화합물
US7517856B2 (en)	2005-10-11	2009-04-14	Ben-Gurion University Of The Negev Research And Development Authority	Bioconjugates comprising sulfated polysaccharides and their uses
CA2692240C (en)	2006-06-22	2018-03-13	Biosurface Engineering Technologies, Inc.	Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
MX2009007688A (es) *	2007-01-18	2009-09-28	Baxter Int	Gel de fibrina para liberacion controlada de tgp-beta y usos del mismo.
WO2008125655A1 (en)	2007-04-13	2008-10-23	Kuros Biosurgery Ag	Polymeric tissue sealant
US8076295B2 (en)	2007-04-17	2011-12-13	Nanotope, Inc.	Peptide amphiphiles having improved solubility and methods of using same
EP2227263A2 (de)	2007-12-28	2010-09-15	Kuros Biosurgery AG	In fibrinschaum integrierte pdgf-fusionsproteine
KR100971271B1 (ko) *	2008-04-28	2010-07-20	한양대학교 산학협력단	헤파린이 결합된 피브린젤, 그 제조방법 및 키트
EP2419116A1 (de)	2009-04-13	2012-02-22	North Western University	Neue peptidbasierte gerüste für knorpelregenerierung und anwendungsverfahren dafür
ES2882852T3 (es)	2011-03-16	2021-12-02	Kuros Biosurgery Ag	Formulación farmacéutica para la utilización en la fusión espinal
EP2816964B1 (de)	2012-02-21	2023-12-27	Ben-Gurion University of The Negev Research and Development Authority	Hydrogelsystem mit räumlich getrennten bioaktiven polypeptiden
WO2014113573A1 (en) *	2013-01-17	2014-07-24	The Regents Of The University Of California	Growth factor sequestering and presenting hydrogels
US10150948B2 (en)	2013-12-11	2018-12-11	The Regents Of The University Of California	Compositions and methods for producing and administering brown adipocytes
US11123404B2 (en)	2016-01-07	2021-09-21	B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University	Methods for generating immunotolerant responses
CN118649290B (zh) *	2024-08-14	2024-12-03	南开大学	一种用于牙周骨缺损再生的纳米纤维膜支架及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1294546C (en) *	1986-04-23	1992-01-21	John S. Sundsmo	Wound healing composition containing collagen
IL90683A0 (en) *	1988-06-27	1990-01-18	Yissum Res Dev Co	Osteogenic growth factors derived from regenerating bone marrow
US4925677A (en) *	1988-08-31	1990-05-15	Theratech, Inc.	Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5654267A (en) *	1988-12-20	1997-08-05	La Jolla Cancer Research Center	Cooperative combinations of ligands contained within a matrix
EP0564502B1 (de) *	1990-11-27	2002-01-30	The American National Red Cross	Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
GB9101183D0 (en) *	1991-01-18	1991-02-27	Univ London	Depot formulations
US5693341A (en) *	1995-03-16	1997-12-02	Collagen Corporation	Affinity bound collagen matrices for the delivery of biologically active agents
CA2217134A1 (en) *	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
GB9722604D0 (en) *	1997-10-28	1997-12-24	Cancer Res Campaign Tech	Heparin-binding growth factor derivatives
AUPP298498A0 (en) *	1998-04-17	1998-05-07	Gropep Pty Ltd	Matrix binding factor
EP1107791B8 (de) *	1998-09-04	2007-11-07	Scios Inc.	Hydrogelzusammensetzungen mit kontrollierter freigabe für die verabreichung von wachstumsfaktoren
DE19841698A1 (de) *	1998-09-11	2000-03-16	Curative Technologies Gmbh	Wachstumsfaktor-enthaltende Zusammensetzung zur Heilung von Gewebeschäden

1999
- 1999-04-22 AT AT99915970T patent/ATE314863T1/de not_active IP Right Cessation
- 1999-04-22 DE DE69929323T patent/DE69929323T2/de not_active Expired - Lifetime
- 1999-04-22 WO PCT/IB1999/000800 patent/WO2000064481A1/en not_active Ceased
- 1999-04-22 EP EP99915970A patent/EP1178834B1/de not_active Expired - Lifetime
- 1999-04-22 JP JP2000613471A patent/JP2002542301A/ja active Pending
- 1999-04-22 CA CA002369579A patent/CA2369579A1/en not_active Abandoned
- 1999-04-22 MX MXPA01010567A patent/MXPA01010567A/es active IP Right Grant
- 1999-04-22 AU AU34381/99A patent/AU3438199A/en not_active Abandoned
- 1999-04-22 ES ES99915970T patent/ES2255257T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2002542301A (ja)	2002-12-10
EP1178834B1 (de)	2006-01-04
ES2255257T3 (es)	2006-06-16
MXPA01010567A (es)	2005-04-29
WO2000064481A1 (en)	2000-11-02
CA2369579A1 (en)	2000-11-02
DE69929323T2 (de)	2006-09-07
DE69929323D1 (de)	2006-03-30
AU3438199A (en)	2000-11-10
EP1178834A1 (de)	2002-02-13

Legal Events

Date	Code	Title	Description
2006-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69929323D1 (de)	2006-03-30	Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
Khatiwala et al.	2007	The regulation of osteogenesis by ECM rigidity in MC3T3‐E1 cells requires MAPK activation
Wood et al.	2009	Controlled release of glial‐derived neurotrophic factor from fibrin matrices containing an affinity‐based delivery system
Bierbaum et al.	2006	Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: characterization and influence on osteoblastic cells
AU4162400A (en)	2000-11-02	Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
CA2371462A1 (en)	2001-09-13	Modified protein matrices
DK0814827T3 (da)	2003-11-10	Karendotel-vækstfaktor-B
DE69832293D1 (de)	2005-12-15	Zubereitungen zur abgabe von negativ geladenen molekülen
EP0653940A4 (de)	1997-02-26	Glialmitogene faktoren, ihre herstellung und verwendung.
CA2266581A1 (en)	1998-03-26	Polymers containing polysaccharides such as alginates or modified alginates
AU3822497A (en)	1998-02-09	Temperature sensitive gel for sustained delivery of protein drugs
ATE189475T1 (de)	2000-02-15	Wachstums-differenzierungsfaktor der tgf-b familie
PT720482E (pt)	2004-07-30	Prosaposina e peptidos derivados da citocina utilizados como agentes
DE69708304D1 (de)	2001-12-20	Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
ATE257711T1 (de)	2004-01-15	Antagonisten der onkogenen aktivität von mdm2, und ihre verwendung in der krebsbehandlung
AR029644A1 (es)	2003-07-10	Proteina aislada, polinucleotido aislado, celula huesped transgenica, metodo para controlar una plaga que no es de mamiferos, cultivo biologicamente puro
Yamada et al.	2010	Biological activity of laminin peptide‐conjugated alginate and chitosan matrices
ATE262537T1 (de)	2004-04-15	Proliferationsinhibitor von endothellzellen und dessen verwendung
DE69712124D1 (de)	2002-05-29	Hormones de croissance humaines mutantes et leur utilisation
ATE193022T1 (de)	2000-06-15	Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
SE0301431D0 (sv)	2003-05-19	Novel antimicrobial peptides
Sahm et al.	1994	The melanocortin (MC3) receptor from rat hypothalamus: Photoaffinity labelling and binding of alanine-substituted α-MSH analogues
ATE336256T1 (de)	2006-09-15	Jodierte proteine zur vorbeugung von jod-mangel zuständen
Anderson et al.	2015	Effective release of a broad spectrum antibiotic from elastin‐like polypeptide‐collagen composite
IT1264447B1 (it)	1996-09-23	Espressione di oncogeni derivati da ntrki in cellule di feocromocitoma pc12 ed utilizzo di questo sistema come screening di sostanze di